Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 5/20 | 0.83 |
| ▸ | ESR2 known ✓ | Q92731 | 4/20 | 0.83 |
| ▸ | LMNA | P02545 | 4/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.83 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.83 |
| ▸ | SHBG | P04278 | 2/20 | 0.83 |
| ▸ | PGR | P06401 | 2/20 | 0.83 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.83 |
| ▸ | AR | P10275 | 2/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.83 |
| ▸ | SNCA | P37840 | 2/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.83 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.83 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.83 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | STS | P08842 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL6331811 | 0.94 | ESR1 (0.83) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL5527393 | 0.94 | ESR1 (0.83) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL4585653 | 0.93 | ESR1 (0.76) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL7989770 | 0.93 | ESR1 (0.89) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL28444514 | 0.93 | ESR1 (0.89) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL2519922 | 0.93 | ESR1 (0.89) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL23743979 | 0.91 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL223226 | 0.91 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Epiestriol SCHEMBL221084 | 0.91 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ACYP2C9 | |
| Estriol SCHEMBL223196 | 0.91 | ESR1 (1.00) | ESR1ESR2LMNAHIF1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 873 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590145-B2 | Vaginal composition comprising a combination of estrogen and vitamin D | CHEMO RESEARCH S.L. (ES) | 2023-02-28 | — | — | US | claimed |
| US-20210069210-A1 | VAGINAL COMPOSITION COMPRISING A COMBINATION OF ESTROGEN AND VITAMIN D | CHEMO RESEARCH S.L. (ES) | 2021-03-11 | — | — | US | claimed |
| EP-3651746-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | Hera Health Solutions Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| CN-111032024-A | Bioerodible drug delivery implant | 赫拉健康解决方案公司 | 2020-04-17 | — | — | CN | claimed |
| US-20190224213-A1 | VAGINAL COMPOSITION COMPRISING A COMBINATION OF ESTROGEN AND VITAMIN D | Chemo Research S.L.. (ES) | 2019-07-25 | — | — | US | claimed |
| EP-3487478-A1 | VAGINAL COMPOSITION COMPRISING A COMBINATION OF ESTROGEN AND VITAMIN D | Chemo Research, S.L. (ES) | 2019-05-29 | — | — | EP | claimed |
| WO-2019014076-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. (US) | 2019-01-17 | — | — | WO | claimed |
| WO-2018015503-A1 | VAGINAL COMPOSITION COMPRISING A COMBINATION OF ESTROGEN AND VITAMIN D | CHEMO RESEARCH S.L. (ES) | 2018-01-25 | — | — | WO | claimed |
| EP-3272333-A1 | VAGINAL COMPOSITION COMPRISING A COMBINATION OF ESTROGEN AND VITAMIN D | Chemo Research, S.L. (ES) | 2018-01-24 | — | — | EP | claimed |
| US-9452175-B2 | Pregnancy hormone combination for treatment of autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-27 | — | — | US | claimed |
| US-5200197-A | Contraceptive pill | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | claimed |
| EP-0500793-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL. | ALZA CORP (US) | 1992-09-02 | — | — | EP | claimed |
| US-5098714-A | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1992-03-24 | — | — | US | claimed |
| EP-0472645-A1 | OSMOTIC DOSAGE FORM. | ALZA CORP (US) | 1992-03-04 | — | — | EP | claimed |
| WO-1991007173-A1 | OSMOTIC, ORAL DOSAGE FORM FOR FERTILITY CONTROL | ALZA CORPORATION (US) | 1991-05-30 | — | — | WO | claimed |
| WO-1990014075-A1 | OSMOTIC DOSAGE FORM | ALZA CORPORATION (US) | 1990-11-29 | — | — | WO | claimed |
| US-4948593-A | SUSTAINED AND CONTROLLED CONTRACEPTION | ALZA CORPORATION (US) | 1990-08-14 | — | — | US | claimed |
| CN-1041528-A | HORMONE PREPARATION AND METHOD | JENCAP RESEARCH LTD (CA) | 1990-04-25 | — | — | CN | claimed |
| US-4826831-A | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | PRE JAY HOLDINGS LIMITED (CA) | 1989-05-02 | — | — | US | claimed |
| EP-0309263-A2 | Hormone composition and use | JENCAP RESEARCH LIMITED (CA) | 1989-03-29 | — | — | EP | claimed |